Sparrow Pharmaceuticals, An Emerging, Clinical-Stage Biopharmaceutical Company, Announced That The First Patient Has Been Dosed In A Phase 2 Clinical Trial (Nct Number: Nct05436652) Of Prednisolone In Combination With Spi-62, Sparrow
Found this useful? Share it with your team.
